Peggy Barnhill, MD
Family Medicine · Whiteville, NCNPI 1407858301
Payments from drug & device makers
Across 255 payments — averaging $128.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Novartis$5K
- Janssen Research & Development, LLC$4K
- GSK$3K
- Novo Nordisk$1K
- Boehringer Ingelheim$747
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,307100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $14,563 |
| Novartis | 3 | $4,590 |
| Janssen Research & Development, LLC | 2 | $4,041 |
| GSK | 5 | $3,257 |
| Novo Nordisk | 68 | $1,366 |
| Boehringer Ingelheim | 4 | $747 |
| Johnson & Johnson | 13 | $587 |
| Amgen(2 entities) | 9 | $571 |
| AbbVie(2 entities) | 25 | $568 |
| Lilly USA, LLC | 27 | $403 |
| Astellas Pharma US Inc | 6 | $306 |
| Bayer | 3 | $262 |
| Paratek Pharmaceuticals, Inc. | 3 | $259 |
| Neurocrine Biosciences, Inc. | 3 | $245 |
| Phathom Pharmaceuticals, Inc. | 2 | $134 |
| Biohaven Pharmaceuticals, Inc. | 2 | $128 |
| Sunovion Pharmaceuticals Inc. | 11 | $107 |
| Merck | 6 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Exact Sciences | 3 | $52 |
| Ironwood Pharmaceuticals, Inc | 3 | $48 |
| Boston Scientific | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Mylan Specialty L.p. | 2 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Abbott | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Insulet Corporation | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,691 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $132,644 |
| FarxigaDapagliflozin Propanediol | 89 | $73,281 |
| MounjaroTirzepatide | 52 | $60,902 |
| JardianceEmpagliflozin | 73 | $58,698 |
| LinzessLinaclotide | 47 | $48,024 |
| EliquisApixaban | 61 | $44,152 |
| Repatha SureclickEvolocumab | 46 | $38,558 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $38,102 |
| TrulicityDulaglutide | 23 | $23,034 |
| JanuviaSitagliptin Phosphate | 15 | $22,087 |
| QuliptaAtogepant | 17 | $20,832 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $19,202 |
| VraylarCariprazine Hcl | 13 | $19,022 |
| RybelsusSemaglutide | 19 | $17,900 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $12,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,366 | $150,544116 claims |
| AbbVieLinzess, Qulipta, Vraylar, Synthroid | $568 | $91,701114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $403 | $83,93675 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $747 | $82,326112 claims |
| AstraZenecaFarxiga, Symbicort | $14,563 | $75,872101 claims |
| PfizerEliquis | $11 | $44,15261 claims |
| GSKTrelegy Ellipta, Shingrix | $3,257 | $43,09759 claims |
| MerckJanuvia | $73 | $22,08715 claims |
| Johnson & JohnsonXarelto | $587 | $11,93611 claims |
| Astellas Pharma US IncMyrbetriq | $306 | $9,25415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $68 | $8,49916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Whiteville
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.